Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy

Journal of Controlled Release

Volumn 162, Issue 1, 2012, Pages 225-232

  Takara, Kazuhiro ^a   Hatakeyama, Hiroto ^a   Kibria, Golam ^a   Ohga, Noritaka ^a   Hida, Kyoko ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Anti angiogenesis; Drug delivery; Drug resistant tumor; Dual ligand; Tumor endothelial cells

Indexed keywords

ANTI-ANGIOGENESIS; ANTI-ANGIOGENIC THERAPY; ANTI-TUMOR ACTIVITIES; CANCER THERAPY; CELL-PENETRATING PEPTIDE; DOXORUBICIN; LIPOSOME MEMBRANES; NEOVASCULATURE; RENAL CELL CARCINOMA; SYSTEMIC ADMINISTRATION; TUMOR CELLS; TUMOR GROWTH; TUMOR VASCULATURE; TUMOR VESSELS; VASCULATURE;

AMINO ACIDS; CYTOLOGY; DRUG DELIVERY; ENDOTHELIAL CELLS; LIPOSOMES; PEPTIDES; POLYETHYLENE GLYCOLS; TUMORS;

LIGANDS;

ARGININE; CELL PENETRATING PEPTIDE; DOXORUBICIN; LIPOSOME; MACROGOL; MICROSOMAL AMINOPEPTIDASE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG TARGETING; ENDOTHELIUM CELL; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN MOTIF; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD13; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY; KIDNEY NEOPLASMS; LIGANDS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; PARTICLE SIZE;

EID: 84864666657     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.06.019     Document Type: Article

References (29)

1. N.J. Vogelzang, and W.N. Stadler Kidney cancer Lancet 352 1998 1691 1696
2. E. Soto-Vega, C. Arroyo, Y. Richaud-Patin, M. García-Carrasco, L.G. Vázquez-Lavista, and L. Llorente P-glycoprotein activity in renal clear cell carcinoma Urol. Oncol. 27 2009 363 366
3. T.E. Hutson Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence Oncologist 16 2011 14 22
4. G.C. Lorenzo, C. Buonerba, M. Biglietto, F. Scognamiglio, B. Chiurazzi, F. Riccardi, and G. Carteni The therapy of kidney cancer with biomolecular drugs Cancer Treat. Rev. 36 2010 S16 S20
5. J. Stevens, and B. St. Croix Tumor endothelial markers W.D. Figg, J. Folkman, Angiogenesis: An Integrative Approach from Science to Medicine 2008 Springer 333 342
6. W. Arap, R. Pasqualini, and E. Ruoslahti Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 279 1998 377 380
7. F. Pastorino, C. Brignole, D. Di Paolo, B. Nico, A. Pezzolo, D. Marimpietri, G. Pagnan, F. Piccardi, M. Cilli, R. Longhi, D. Ribatti, A. Corti, T.M. Allen, and M. Ponzoni Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy Cancer Res. 66 2006 10073 10082
8. E.A. Murphy, B.K. Majeti, L.A. Barnes, M. Makale, S.M. Weis, K. Lutu-Fuga, W. Wrasidlo, and D.A. Cheresh Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis Proc. Natl. Acad. Sci. U. S. A. 105 2008 9343 9348
9. Y. Murase, T. Asai, Y. Katanasaka, T. Sugiyama, K. Shimizu, N. Maeda, and N. Oku A novel DDS strategy, dual-targeting, and its application for antineovascular therapy Cancer Lett. 287 2010 165 171
10. K. Takara, H. Hatakeyama, N. Ohga, K. Hida, and H. Harashima Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake Int. J. Pharm. 396 2010 143 148
11. G. Kibria, H. Hatakeyama, N. Ohga, K. Hida, and H. Harashima Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery J. Control. Release 153 2011 141 148
12. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
13. H. Hatakeyama, H. Akita, and H. Harashima A multifunctional envelope type nano device (MEND) for drug and gene delivery to tumors based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Deliv. Rev. 63 2011 152 160
14. M.E. Davis, Z. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782
15. T.A. ElBayoumi, and V.P. Torchilin Tumor-specific anti-nucleosome antibody improves therapeutics efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice Mol. Pharm. 6 2009 246 254
16. H. Hatakeyama, H. Akita, K. Maruyama, T. Suhara, and H. Harashima Factor governing the in vivo tissue uptake of transferring coupled polyethylene glycol liposomes in vivo Int. J. Pharm. 281 2004 25 33
17. K. Hida, Y. Hida, D.N. Amin, A.F. Flint, D. Panigrahy, C.C. Morton, and M. Klagsbrun Tumor-associated endothelial cells with cytogenetic abnormalities Cancer Res. 15 2004 8249 8255
18. N. Ohga, K. Hida, Y. Hida, C. Muraki, K. Tsuchiya, K. Matsuda, Y. Ohiro, Y. Totsuka, and M. Shindoh Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells Cancer Sci. 100 2009 1963 1970
19. K. Matsuda, N. Ohga, Y. Hida, C. Muraki, K. Tsuchiya, T. Kurosu, T. Akino, S.C. Shih, Y. Totsuka, M. Klagsbrun, M. Shindoh, and K. Hida Isolated tumor endothelial cells maintain specific character during long-term culture Biochem. Biophys. Res. Commun. 394 2010 947 954
20. T. Akino, K. Hida, Y. Hida, K. Tsuchiya, D. Freedman, C. Muraki, N. Ohga, K. Matsuda, K. Akiyama, K. Harabayashi, M. Klagsburn, and M. Shindoh Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors Am. J. Pathol. 175 2009 2657 2667
21. C. Muraki, N. Ohga, Y. Hida, H. Nishihara, Y. Kato, K. Tsuchiya, K. Matsuda, Y. Totsuka, M. Shindoh, and K. Hida Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells Int. J. Cancer 130 2012 59 70
22. T. Kurosu, N. Ohga, Y. Hida, N. Maishi, K. Akiyama, W. Kakuguchi, T. Kuroshima, M. Kondo, T. Akino, Y. Totsuka, M. Shindoh, F. Higashino, and K. Hida HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium Br. J. Cancer 104 2011 819 829
23. K. Maruyama, T. Yuda, A. Okamoto, S. Kojima, A. Suginaka, and M. Iwatsuru Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol) Biochim. Biophys. Acta 1128 1992 44 49
24. 1-containing liposomes Biochim. Biophys. Acta 1104 1992 95 101
25. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 160
26. T.M. Allen Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2 2002 750 763
27. Y. van Hensvergen, H.J. Broxterman, Y.W. Elderkamp, J. Lankelma, J.C. Beers, M. Heijn, B. Epie, K. Hoekman, and H.M. Pinedo A doxorubicin-CNGRC- peptide conjugate with prodrug properties Biochem. Pharmacol. 63 2002 897 908
28. F. Gentile, A. Curcio, C. Indolfi, M. Ferrari, and P. Decuzzi The margination propensity of spherical particles for vascular targeting in the microcirculation J. Nanobiotechnol. 6 2008 1 9
29. J.Y. Zheng, D. Chen, J. Chan, D. Ui, E. Ko, and S. Pang Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A Cancer Gene Ther. 10 2003 764 770